UNII C151H8M554

SUCROSE

Unique Ingredient Identifier C151H8M554 is listed as a ingredient substance
UniiC151H8M554
Preferred Substance NameSUCROSE
Rn57-50-1
Ec200-334-9
NcitC68477
Rxcui10159
Pubchem5988
Molecular FormulaC12H22O11
InchikeyCZMRCDWAGMRECN-UGDNZRGBSA-N
SmilesOC[[email protected]]1O[[email protected]@](CO)(O[[email protected]]2O[[email protected]](CO)[[email protected]@H](O)[[email protected]](O)[[email protected]]2O)[[email protected]@H](O)[[email protected]@H]1O
Unii TypeINGREDIENT SUBSTANCE
RN57-50-1
EC200-334-9
NCITC68477
RXCUI10159
MFC12H22O11
INCHI KEYCZMRCDWAGMRECN-UGDNZRGBSA-N
SMILESOC[[email protected]]1O[[email protected]@](CO)(O[[email protected]]2O[[email protected]](CO)[[email protected]@H](O)[[email protected]](O)[[email protected]]2O)[[email protected]@H](O)[[email protected]@H]1O

Alternate Names

Dosage Forms

UNII C151H8M554 SUCROSE is commonly included in medications in the following forms.

RouteDosage FormPotency
BUCCALTABLET16.6 MG
BUCCAL/SUBLINGUALTABLET91 MG
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED6.84 %
INTRAMUSCULARSOLUTION, INJECTION7.29 %W/V
INTRAVENOUSINJECTION19.5 %
INTRAVENOUSINJECTION, EMULSION54 MG/1ML
INTRAVENOUSINJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSP90 %
INTRAVENOUSINJECTION, SUSPENSION, LIPOSOMAL9.4 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION20 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED54 mg/vial
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED7.78 %
INTRAVENOUSPOWDER, FOR RECONSTITUTION40 %
INTRAVENOUSSOLUTION, INJECTION NA
INTRAVENOUSSOLUTION, LIPOSOME, INJECTION8.5 %
IV(INFUSION)INJECTION, LIPOSOMAL1 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED54 MG/1VIAL
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED5.4 %
ORALCAPSULE527.43 MG
ORALCAPSULE, DELAYED ACTION175.14 MG
ORALCAPSULE, DELAYED RELEASE48 MG
ORALCAPSULE, ENTERIC COATED PELLETS140.76 MG
ORALCAPSULE, EXTENDED RELEASE396.14 MG
ORALCAPSULE, HARD GELATIN NA
ORALCAPSULE, SUSTAINED ACTION481.7 MG
ORALCONCENTRATE4250 MG/5ML
ORALDROPS755.5 MG/2.5ML
ORALEMULSION NA
ORALFOR SUSPENSION3041 MG/5ML
ORALGRANULE3024.2 MG
ORALGRANULE, FOR ORAL SOLUTION1774.84 MG/5ML
ORALGRANULE, FOR ORAL SUSPENSION11 MG
ORALGRANULE, FOR RECONSTITUTION2669.8 MG
ORALGRANULE, FOR SUSPENSION2942.7 MG
ORALGRANULE, FOR SUSPENSION, EXTENDED RELEASE NA
ORALLIQUID720 MG/1ML
ORALLIQUID250 MG/ML
ORALLIQUID6.25 g/10mL
ORALLIQUID,EXTENDED RELEASE0.8 MG/ML
ORALPASTILLE426 MG
ORALPOWDER4187 MG/1PKT
ORALPOWDER4187 MG/1SCP
ORALPOWDER, FOR ORAL SOLUTION1933.3 MG
ORALPOWDER, FOR ORAL SUSPENSION4636 mg
ORALPOWDER, FOR ORAL SUSPENSION3643 MG/1PKT
ORALPOWDER, FOR ORAL SUSPENSION3643 MG/1SCP
ORALPOWDER, FOR ORAL SUSPENSION1195.44 MG/5ML
ORALPOWDER, FOR RECONSTITUTION2322.79 MG/5ML
ORALPOWDER, FOR SOLUTION1892.86 MG/2GM
ORALPOWDER, FOR SUSPENSION9700 MG
ORALPOWDER, FOR SUSPENSION166 MG/5ML
ORALSOLUTION21000 MG/30ML
ORALSOLUTION2000 MG/5ML
ORALSOLUTION30.51 %W/W
ORALSOLUTION NA
ORALSOLUTION, ELIXIR2600 MG/5ML
ORALSOLUTION, SYRUP2255 MG/5ML
ORALSUSPENSION8500 MG/5ML
ORALSUSPENSION952.42 MG/5 ML
ORALSUSPENSION375 mg/1.25mL
ORALSUSPENSION44.44 %W/V
ORALSUSPENSION, DROPS1250 MG/2.5ML
ORALSUSPENSION, EXTENDED RELEASE1350 MG/5ML
ORALSUSPENSION, LIQUID1750 MG/5ML
ORALSUSPENSION, SUSTAINED ACTION2323.3 MG/1PKT
ORALSUSPENSION, SUSTAINED ACTION600 MG/5ML
ORALSUSPENSION, SYRUP, SUSTAINED ACTION10 %
ORALSYRUP85.46 %
ORALSYRUP2.9 g/5mL
ORALTABLET9700 MG
ORALTABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE2400 MG
ORALTABLET, CHEWABLE14.78 MG
ORALTABLET, COATED400 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED279.5 MG
ORALTABLET, DELAYED RELEASE33.5 MG
ORALTABLET, EXTENDED RELEASE185.07 MG
ORALTABLET, FILM COATED200 MG
ORALTABLET, REPEAT ACTION129.55 MG
ORALTABLET, SUGAR COATED73.18 MG
ORALTABLET, SUSTAINED ACTION284.54 MG
ORALTABLET, SUSTAINED ACTION, FILM COATED119.12 MG
ORALTABLET, UNCOATED, LOZENGE1255 MG
ORALTABLET, UNCOATED, TROCHE NA
ORALWAFER NA
RECTALLIQUID NA
RECTALSOLUTION35.42 %
SUBCUTANEOUSINJECTION17 %
SUBCUTANEOUSINJECTION, SUSPENSION, EXTENDED RELEASE0.8 MG/0.85 ML
SUBCUTANEOUSMICROCAPSULES FOR INJECTION SUSPENSION, STERILE0.08 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED8.21 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 4.1 %
SUBCUTANEOUSSOLUTION, INJECTION7.29 %
SUBLINGUALTABLET17 MG
TOPICALOINTMENT20 %W/W
TRANSMUCOSALTABLET, UNCOATED, LOZENGE100.35 MG

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.